ImpediMed secures $15.2M for strategic growth
Medical technology innovator ImpediMed (ASX:IPD) announced a $15.2 million capital raise.
The funding package is headlined by a two-tranche placement of $13.2 million at $0.010 per share, which saw robust backing from both institutional and sophisticated investors.
Demonstrating strong internal confidence, the company’s directors personally committed $0.6 million to the placement.
To further bolster its balance sheet, ImpediMed is launching a share purchase plan for eligible Australian and New Zealand shareholders, aiming to raise an additional $2 million.
These fresh funds are earmarked for strategic debt reduction and the aggressive commercial scaling of the SOZO platform, with a primary focus on the high-value United States market.
Beyond the capital injection, the company is implementing rigorous cost-out initiatives designed to trim $5 million from annual operating expenses.
The dual-pronged approach—combining fresh equity with operational discipline—provides a clear runway towards operating cash flow breakeven by FY28.
The placement also includes an attractive incentive for participants: one free attaching option per share, with the potential for a secondary option upon exercise.
While the first $3 million of the placement is immediate, the remainder of the raise and the issuance of options await shareholder approval at an extraordinary general meeting scheduled for mid-June.
At the time of reporting, ImpediMed’s share price was $0.0090.
